MedTrace Logo

Liquid Biopsy Monitoring Of EGFR T790M in Advanced Non-Small Cell Lung Cancer

NCT07475637 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2026-03-19

No results posted yet for this study

Summary

The goal of this retrospective observational study is to assess the clinical utility of plasma-based EGFR testing for detection and longitudinal monitoring of the acquired T790M resistance mutation in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with first- or second-generation EGFR tyrosine kinase inhibitors in routine clinical practice in Tunisia.

The main questions it aims to answer are:

* What is the detection rate of EGFR T790M mutation in plasma at the time of disease progression?
* Does repeated liquid biopsy increase the cumulative detection of T790M?
* Is T790M emergence associated with baseline clinical and molecular characteristics?
* Is T790M status associated with progression-free survival? Participants underwent plasma sampling for circulating tumor DNA analysis during follow-up, and clinical and molecular data were retrospectively collected from medical records to evaluate mutation dynamics and outcomes.

Conditions

Sponsors & Collaborators

  • Hopital Charles Nicolle

    collaborator OTHER

  • Faculty of Medicine of Tunis

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2025-12-30
Completion
2025-12-30

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07475637 on ClinicalTrials.gov